Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Breier

Showing results (211-220 of 269) with videos related to

Pageof 27
Sort By:
Archives of General Psychiatry|July 1, 1986
Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatmentD Pickar, R Labarca, A R Doran, et al.
The Journal of Clinical Psychiatry|June 10, 2000
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in SchizophreniaJ C Gómez, J A Sacristán, J Hernández, et al.
The Journal of Physical Chemistry. A|April 23, 2019
Infrared Spectroscopy of Disilicon-Carbide, Si<sub>2</sub>C: The ν<sub>3</sub> Fundamental BandDaniel Witsch, Volker Lutter, Alexander A Breier, et al.
International Clinical Psychopharmacology|August 15, 2002
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work statusL Shi, M A Namjoshi, F Zhang, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 14, 1999
Mechanism of peripheral noradrenergic stimulation by clozapineI Elman, D S Goldstein, G Eisenhofer, et al.
Synapse (New York, N.Y.)|May 21, 1998
Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approachA Breier, C M Adler, N Weisenfeld, et al.
Biological Psychiatry|May 16, 1998
Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging studyA Bertolino, J H Callicott, I Elman, et al.
Archives of General Psychiatry|March 11, 2000
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophreniaS E Purdon, B D Jones, E Stip, et al.
International Journal of Geriatric Psychiatry|December 19, 2001
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementiaJ S Street, W S Clark, D L Kadam, et al.
Molecular and Cellular Biochemistry|December 24, 1997
Mechanisms that may be involved in calcium tolerance of the diabetic heartA Ziegelhöffer, T Ravingerová, J Styk, et al.
Pageof 27

Showing results (211-220 of 269) with videos related to

Sort By:
Pageof 27
Archives of General Psychiatry|July 1, 1986
Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatmentD Pickar, R Labarca, A R Doran, et al.
The Journal of Clinical Psychiatry|June 10, 2000
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in SchizophreniaJ C Gómez, J A Sacristán, J Hernández, et al.
The Journal of Physical Chemistry. A|April 23, 2019
Infrared Spectroscopy of Disilicon-Carbide, Si<sub>2</sub>C: The ν<sub>3</sub> Fundamental BandDaniel Witsch, Volker Lutter, Alexander A Breier, et al.
International Clinical Psychopharmacology|August 15, 2002
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work statusL Shi, M A Namjoshi, F Zhang, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 14, 1999
Mechanism of peripheral noradrenergic stimulation by clozapineI Elman, D S Goldstein, G Eisenhofer, et al.
Synapse (New York, N.Y.)|May 21, 1998
Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approachA Breier, C M Adler, N Weisenfeld, et al.
Biological Psychiatry|May 16, 1998
Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging studyA Bertolino, J H Callicott, I Elman, et al.
Archives of General Psychiatry|March 11, 2000
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophreniaS E Purdon, B D Jones, E Stip, et al.
International Journal of Geriatric Psychiatry|December 19, 2001
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementiaJ S Street, W S Clark, D L Kadam, et al.
Molecular and Cellular Biochemistry|December 24, 1997
Mechanisms that may be involved in calcium tolerance of the diabetic heartA Ziegelhöffer, T Ravingerová, J Styk, et al.
Pageof 27